A detailed history of Hantz Financial Services, Inc. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Hantz Financial Services, Inc. holds 3 shares of CPRX stock, worth $72. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3
Holding current value
$72
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025

BUY
$19.53 - $25.74 $58 - $77
3 New
3 $0

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.5B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Hantz Financial Services, Inc. Portfolio

Follow Hantz Financial Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hantz Financial Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hantz Financial Services, Inc. with notifications on news.